Differences In Estrogen And Progesterone Receptor Expression In Endometrial Polyps And Atrophic Endometrium Of Postmenopausal Women With And Without Exposure To Tamoxifen. by Leão, Rogerio Barros Ferreira et al.
MOLECULAR AND CLINICAL ONCOLOGY  1:  1055-1060,  2013
Abstract. Postmenopausal women who use tamoxifen present 
with an increased incidence of endometrial alterations, such 
as polyps and hyperplasia, in addition to a higher risk of 
malignant endometrial neoplasms. Among these endometrial 
changes, polyps are the most common, with a pathogenesis 
associated with hormonal influence. The objective of this 
study was to compare the expression of estrogen recep-
tors (ERs) and progesterone receptors (PRs) in endometrial 
polyps from tamoxifen users with that in endometrial polyps 
and the atrophic endometrium of postmenopausal tamoxifen 
non-users. Among women undergoing surgical hysteroscopy, 
84 tamoxifen users with benign endometrial polyps were 
selected. This group was compared to 84 samples of atrophic 
endometrium and to 252 benign polyps from postmenopausal 
women who were not treated with tamoxifen. The expression 
of ER̸PR was assessed by immunohistochemical analysis, 
according to the percentage of stained cells, intensity of nuclear 
staining and final score. The polyps from tamoxifen users 
exhibited a higher expression of ER and PR in the glandular 
epithelium and stroma compared to the atrophic endometrium 
(P<0.0001). Compared to the polyps from women not treated 
with tamoxifen, tamoxifen users exhibited a higher PR expres-
sion in the epithelium (P=0.0014) and stroma (P=0.0056), with 
no difference in the expression of ER. In conclusion, endome-
trial polyps frequently exhibit an increase in ER expression, 
regardless of tamoxifen use. High levels of PR expression 
appear to be consistent with the estrogen agonist effects of 
tamoxifen.
Introduction
Tamoxifen is an antineoplastic drug used in the treat-
ment of estrogen receptor (ER)-positive breast cancer (1). 
The mechanism of action of tamoxifen in breast cancer 
is the inhibition of cancer cell growth by the competitive 
antagonism of estrogen at the ER (2). In the classic model 
of estrogen stimulation, estrogen binds to the ER, which is 
inactive in the nucleus, inducing conformational changes in 
the receptor, facilitating its binding to specific DNA sites 
(referred to as estrogen response elements) and to coactivator 
proteins (amplified in breast 1, CREB-binding protein/p300 
and steroid receptor coactivator-3), which activate the genes 
that encode progesterone receptors (PRs), as well as those that 
encode mitogenic growth factors, such as transforming growth 
factor-α, vascular endothelial growth factor, platelet-derived 
growth factor, insulin-like growth factor 1 and insulin receptor 
substrate (2-5). In breast cells, the tamoxifen-receptor complex 
recruits nuclear receptor corepressor and silencing mediator of 
retinoic acid and thyroid hormone receptor, thereby repressing 
the transcription of these genes (6).
However, despite its antagonist effect on breast tissue, 
tamoxifen behaves as a partial estrogen agonist in the endo-
metrium (7). During the premenopausal period, when estrogen 
concentrations are high, tamoxifen exerts an antagonist effect, 
whereas during the postmenopausal period, when estrogen 
concentrations are low, it exerts an agonist effect (8).
A higher incidence of endometrial alterations, such as 
polyps, hyperplasia, carcinoma and sarcoma, have been 
reported in menopausal tamoxifen users, in addition to an 
increased risk of endometrial malignant neoplasms (9-14).
Among the endometrial alterations reported in tamoxifen 
users, polyps are the most common, with a prevalence of 
13-30% (10,12,15,16). In patients treated with tamoxifen, 
microscopic analysis revealed that polyps are more translu-
cent, edematous and fibrotic, with less stromal cellularity (10).
The stimulating factor for focal endometrial growth has 
not been determined. However, it has been hypothesized 
that a significant hormonal influence exists. Previous studies 
demonstrated a higher ER expression in the epithelium and 
stroma of the endometrial polyps from menopausal patients 
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in comparison to the adjacent atrophic endometrium (17-19). 
With regard to the expression of PR, previous studies have 
demonstrated a higher expression in the epithelium and not 
the stroma of the polyp, compared to the adjacent atrophic 
endometrium (17-20). This finding suggests that endometrial 
polyps have a higher sensitivity to estrogen and progesterone 
and may develop even in the presence of low serum hormone 
concentrations (19).
Previous studies comparing polyps from tamoxifen users to 
those from non-users have reported lower ER expression and 
increased PR expression in tamoxifen users, demonstrating 
an agonist effect of tamoxifen on the endometrium. However, 
only few small case studies are available, reporting variable 
results (21-24).
Therefore, the pathophysiology and malignant potential 
of endometrial polyps have not been fully elucidated, nor 
has the mechanism underlying the tamoxifen-induced endo-
metrial alterations. Increased knowledge of the hormonal 
factors involved in this process may contribute to a better 
understanding of this disorder and the optimal approach may 
be applied in the treatment of endometrial diseases in breast 
cancer patients using adjuvant therapy with tamoxifen.
The aim of this study was to assess the expression of 
ER̸PR in the endometrial polyps from menopausal tamoxifen 
users, compared to that in the atrophic endometrium and in 
polyps from menopausal women who were not treated with 
tamoxifen.
Materials and methods
Data collection. This study was conducted in the 
Professor Dr José Aristodemo Pinotti Women's Hospital 
(CAISM/UNICAMP) and was approved by the Research 
Ethics Committee of the State University of Campinas 
(protocol no. 004/2010). According to the information retrieved 
from the computerized database of this institution, a total of 
1,050 women underwent surgical hysteroscopy for endometrial 
polypectomy between January, 1998 and December, 2008. All 
the premalignant or malignant polyps were excluded from this 
study. From the entire sample, the postmenopausal tamoxifen 
users histologically diagnosed with benign endometrial polyp 
and normal adjacent endometrium, as evaluated by hyster-
oscopy, were selected (n=84). This group was compared to 
two other groups of women: a second group of 84 samples of 
atrophic endometrium obtained from postmenopausal women 
who did not receive hormone therapy (HT) and a third group 
of benign polyps from postmenopausal non-users of tamoxifen 
with no previous history of HT use. For this latter group, 
three controls (tamoxifen non-users with polyps) were selected 
for each polyp from tamoxifen users, totaling 252 females. 
The subjects were selected by simple random sampling. The 
sample units were uniformly distributed (all subjects had 
the same probability of being selected) using SAS software, 
version 9.2 (SAS Institute Inc., Cary, NC, USA).
Clinical, histopathological and hysteroscopic findings were 
collected from patient records. The clinical characteristics 
assessed were age, postmenopausal bleeding, arterial hyper-
tension, obesity and diabetes mellitus.
A surgical hysteroscopy was performed by a gynecologist, 
with the patient under spinal anesthesia. A 10-mm monopolar 
gynecologic resectoscope with a loop electrode was used 
for the procedure (Karl Storz GmbH & Co. KG, Tuttlingen, 
Germany). A 1.5% glycine solution was used for the distension 
of the uterine cavity. The endocervical canal and uterine cavity 
were assessed and hysteroscopic resection was performed 
using monopolar energy.
The endometrial samples were analyzed by pathologists of 
the Department of Pathological Anatomy of the UNICAMP 
School of Medicine, using hematoxylin and eosin (H&E) 
staining.
Construction of tissue microarray (TMA). Initially, a patholo-
gist from the Department of Pathological Anatomy at the 
UNICAMP School of Medicine examined the sections repre-
sentative of H&E stained endometrial polyps. Two regions that 
best represented the stroma and glandular epithelium were 
selected for the construction of TMA and a technique validated 
for the endometrium was adopted (25). The selected regions 
were then identified in the archival paraffin blocks (donor 
block). Subsequently, the marked donor blocks were sent to the 
Laboratory of Immunohistochemistry in the Department of 
Pathological Anatomy of the A.C. Camargo Cancer Hospital 
(São Paulo, Brazil) for the construction of recipient blocks 
with the TMA technique. A tissue microarrayer (Beecher 
Instruments, Silver Spring, MD, USA) available at the 
Department of Pathological Anatomy of the AC Camargo 
Cancer Hospital was used. Cylinder cones (1.0 mm) from the 
region of interest were obtained and transferred to a new block 
with a two-dimensional layout and intercore spacing of 0.2 mm, 
as determined and recorded by the equipment. From this new 
block, referred to as the ‘recipient block’, histological sections 
were obtained with a manual microtome and transferred using 
adhesive tape to special adhesive-coated slides (Instrumentics 
Inc., Hackensack, NJ, USA). The adhesive tape was removed 
under exposure to ultraviolet light and the slides were stored, 
paraffin-embedded, vacuum-packed and frozen at -20˚C.
Immunohistochemistry. ER and PR expression was assessed in 
the Laboratory of Immunohistochemistry of the Department 
of Pathology at the A.C. Camargo Cancer Hospital. The 
5-µm TMA sections were deparaffinized for 24 h at 60˚C in 
an incubator. Subsequently, the slides were rinsed in xylene 
at 60˚C for 20 min, followed by xylene at room temperature 
for 20 min, 100% ethanol for 30 sec, 85% ethanol for 30 sec 
and 70% ethanol for 30 sec. The slides were then washed in 
distilled tap water.
A citrate buffer solution (10 mM, pH 6.0) was heated to 
boiling point in an Eterna pressure cooker (Nigro, Araraquara, 
Brazil) without sealing the lid, immersing the slides into boiling 
retrieval buffer. The cooker was sealed with the safety valve in 
the open position. Following release of the saturated vapor, the 
safety valve was lowered until total pressurization. Timing of the 
duration of antigen retrieval was initiated (~4 min). The cooker 
remained closed under tap water until complete depressurization 
was achieved. The lid of the cooker containing the slides was 
removed and the slides were washed in distilled tap water.
An endogenous peroxidase block was performed with 
3% hydrogen peroxide (H2O2-10 vol) with 3 changes of 10 min 
each. The slides were washed with distilled tap water and 
phosphate buffered saline (PBS; 10 mM, pH 7.4) for 5 min.
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The slides were incubated with the primary antibody 
diluted in predetermined titer in PBS buffer containing 
1% bovine serum albumin (A9647; Sigma-Aldrich, St. Louis, 
MO, USA) and 0.1% sodium azide (NaN3) for 18 h in a 
humidity chamber at 4˚C. Primary monoclonal antibodies 
against ER (code M7047, clone 1D5, dilution 1:250; Dako, 
Carpinteria, CA, USA) and PR (code M3569, clone PgR 636, 
dilution 1:500; Dako) were used in the procedure.
The slides were washed in PBS buffer with 3 changes of 
3 min each, incubated for 30 min at 37˚C with Advance™ HRP 
Link (code no. K4068; Dako) and washed with PBS buffer, with 
3 changes of 3 min each. The slides were subsequently incubated 
with Advance HRP Enzyme for 30 min at 37˚C and washed 
with PBS buffer, with 3 changes of 3 min each. The slides were 
incubated in substrate solution consisting of 100 mg 3,3' diami-
nobenzidine tetrahydrochloride (code D-5637, Sigma-Aldrich), 
1 ml of dimethyl sulphoxide, 1 ml of 6% H2O2 (20 vol) and 
100 ml PBS for 5 min at 37˚C and protected from light. The 
slides were washed in distilled tap water for 3 min and coun-
terstained with Harris' hematoxylin for 1 min. The slides were 
then thoroughly washed in distilled tap water and immersed 
twice in ammonium water (0.5% ammonium hydroxide solu-
tion), followed by washing in distilled tap water. The slides 
were dehydrated in 80% ethanol for 30 sec, 95% ethanol for 
30 sec, twice in 100% ethanol for 30 sec̸time and 4 times 
in xylene for 30 sec̸time. The slides were then mounted in 
Entellan® Neu (code 1.07961; Merck, Darmstadt, Germany). 
Upon examination under a light microscope, a golden brown 
precipitate was observed as a final reaction product that varied 
according to the type of receptor.
Immunohistochemistry reading. The TMA slides were 
manually examined by a single pathologist under a conven-
tional light microscope. The expression of ER and PR was 
assessed in the stroma and glandular epithelium of the polyps 
and evaluated using a semiquantitative method of nuclear 
reaction through the analysis of the percentage of stained 
cells, intensity of nuclear staining and final score (26). The 
percentage of stained cells was visually estimated and catego-
rized in the following manner: grade 0, none stained; grade 1, 
<1% of cells stained; grade 2, 1-10% of cells stained; grade 3, 
11-33% of cells stained; grade 4, 34-66% of cells stained; and 
grade 5, >66% of cells stained. With regard to the intensity 
of nuclear staining, grading was as follows: grade 0, nega-
tive; grade 1, weak reaction; grade 2, moderate reaction; and 
grade 3, intense reaction (26). The sum of positivity and inten-
sity resulted in a final score, ranging from 0-8 (excluding the 
value of 1). Appropriate positive and negative controls were 
used. According to Harvey et al (26) this scoring method is 
easy to learn and highly reproducible, with a κ index of 0.87.
Statistical analysis. The clinical characteristics between the 
3 groups (benign polyps and tamoxifen users; atrophic endo-
metrium; and benign polyps from tamoxifen non-users) were 
compared using the Chi-square test and Fisher's exact test, 
corrected by the Bonferroni method, and the Kruskal-Wallis 
test (27,28).
The mean final scores of ER and PR expression in the 
glandular epithelium and stroma of the polyps from tamoxifen 
users was separately compared to the mean scores of ER and 
PR in the glandular epithelium and stroma of the atrophic 
Table I. Clinical characteristics of postmenopausal tamoxifen users with benign polyps, tamoxifen non-users with benign polyps 
and tamoxifen non-users with atrophic endometrium (n=420).
 Atrophic Polyps from Polyps from
 endometrium tamoxifen users tamoxifen non-users
 (n=84) (n=84) (n=252)
 ------------------------------------------- ------------------------------------------ --------------------------------------------
Characteristics No. Percentage P-valuea No. Percentage P-valueb No. Percentage
Postmenopausal
bleeding   1.0000   <0.0001c  
  Yes 7 9.6  7 8.5  103 41.9
  No 66 90.4  75 91.5  143 48.1
Arterial
hypertension   0.3717   0.4362  
  Yes 35 47.9  50 60.2  173 68.9
  No 38 52.1  33 39.8  78 31.1
DM   0.6336   0.0531  
  Yes 8 11.0  15 18.1  79 31.6
  No 65 89.0  68 81.9  171 68.4
BMI   1.0000   <0.0001c  
  <30 48 66.7  57 67.9  105 42.3
  ≥30 24 33.3  27 32.1  143 57.7
P-values were calculated with the Chi-square test/Fisher's exact test. aAtrophic endometrium vs. polyp with tamoxifen. bPolyp with tamoxifen 
vs. polyp without tamoxifen. cP-value corrected by the Bonferroni method (independent tests). DM, diabetes mellitus; BMI, body mass index.
LEAO et al:  ESTROGEN AND PROGESTERONE RECEPTOR IN ENDOMETRIAL POLYPS1058
endometrium and the polyps from tamoxifen non-users, 
using the Mann-Whitney test corrected by the Bonferroni 
method (27,28). SAS software, version 9.2 was used and P<0.05 
was considered to indicate a statistically significant difference.
Results
Patient characteristics. The mean age of patients with benign 
polyps who used tamoxifen was 62.8 years (SD ± 9.5), of 
patients with atrophic endometrium 63.1 years (SD ± 8.6) 
and of patients with benign polyps who did not use 
tamoxifen 61.2 years (SD ± 7.8). There was no statistically 
significant difference between the 3 groups (P=0.1737). The 
mean duration of tamoxifen use was 31.7 months (SD ± 18.8) 
(data not shown). Postmenopausal bleeding and obesity were 
more common among women with polyps who were not 
treated with tamoxifen (Table I).
Hormone receptor expression. Comparing the mean final 
score for ER and PR, the polyps from tamoxifen users exhib-
ited a higher ER/PR expression in the glandular epithelium 
and the stroma compared to the atrophic endometrium, with 
a statistically significant difference (P<0.0001). Compared 
to the polyps from women who had not been treated with 
tamoxifen, tamoxifen users exhibited a higher PR expression 
in the epithelium and stroma, with a statistically significant 
Table II. Final estrogen receptor (ER) and progesterone receptor (PR) score in the glandular epithelium and stroma of benign 
polyps from tamoxifen users, benign polyps from tamoxifen non-users and atrophic endometrium (n=420).
 Atrophic Polyps from Polyps from
 endometrium tamoxifen users tamoxifen non-users
 --------------------------------------------- ---------------------------------------------- ---------------------------------------------
Final score No. Mean SD P-valuea No. Mean SD P-valueb No. Mean SD
ER gland 77 0.1 0.7 <0.0001c 82 5.3 0.7 1.0000 247 5.9 3.2
ER stroma 77 0.1 0.6 <0.0001c 83 4.8 0.6 1.0000 249 5.4 3.2
PR gland 82 0.7 2.3 <0.0001c 82 7.5 2.3 0.0014c 243 6.6 1.1
PR stroma 83 0.6 2.0 <0.0001c 83 6.3 2.0 0.0056c 245 5.3 1.6
P-values calculated with the Mann-Whitney test. aAtrophic endometrium vs. polyp with tamoxifen. bPolyp with tamoxifen vs. polyp without 
tamoxifen. cP-value corrected by the Bonferroni method (independent tests). BMI, body mass index; SD, standard deviation.
Table III. Comparison of the combination of final estrogen receptor (ER) and progesterone receptor (PR) scores in the glandular 
epithelium and stroma of benign polyps from tamoxifen users, benign polyps from tamoxifen non-users and atrophic endome-
trium (n=420).
 Atrophic Polyps from Polyps from
 endometrium tamoxifen users of tamoxifen non-users
 -------------------------------------------- ------------------------------------------- ---------------------------------------------
Final score No. Percentage P-valuea No. Percentage P-valueb No. Percentage
ER/PR epithelium   <0.0001c   1.0000d
  ER+/PR+ 0 0.0  60 74.1  197 82.4
  ER+/PR- 3 4.0  1 1.2  9 3.8
  ER-/PR+ 8 10.7  20 24.7  25 10.5
Receptor-positive 11c 14.7c  81c 100c  231c 97.6c
ER-/PR- 64c 85.3c  0c 0c  8c 3.3c
ER/PR stroma   <0.0001c   1.0000d
  ER+/PR+ 0 0  58 70.7  187 77.3
  ER+/PR- 2 2.6  1 1.2  16 6.6
  ER-/PR+ 7 9.2  22 26.8  28 11.6
Receptor-positive 9 11.8  81 98.8  231 95.5
  ER-/PR- 67 88.2  1 1.2  11 4.5
P-values were calculated with the Chi-square test/Fisher's exact test. aAtrophic endometrium vs. polyp with tamoxifen. bPolyp with tamox-
ifen vs. polyp without tamoxifen. cP-value corrected by the Bonferroni method (independent tests). dCalculated with the Fisher's exact test. 
BMI, body mass index.
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difference. Despite the lower ER expression in the glandular 
epithelium and stroma of the polyps from tamoxifen users, 
there was no statistically significant difference compared to 
the polyps from tamoxifen non-users (Table II).
On evaluating the combination of ER and PR expression 
in the atrophic endometrium, we observed that the majority 
of cases were ER-/PR- in the epithelium and the stroma. 
There were no ER+/PR+ cases. However, in the polyps from 
tamoxifen users as well as those from non-users, there was a 
high percentage of cases with hormone receptor positivity, the 
majority of which were ER+/PR+ (Table III).
Discussion
This study was conducted to evaluate the effect of tamoxifen 
on the expression of ER/PR in endometrial polyps from post-
menopausal women. The results demonstrated that the polyps 
from tamoxifen users exhibited a higher ER/PR expression 
compared to the atrophic endometrium and a higher PR 
expression compared to the polyps from tamoxifen non-users.
To the best of our knowledge, this study on the immuno-
histochemical expression of hormone receptors in polyps from 
tamoxifen users is the largest case study in the literature to 
compare these three types of endometrial histology.
In the present study, we observed that the final score of 
ER̸PR expression in the glandular epithelium and the stroma 
was significantly higher in polyps from tamoxifen users 
compared to the atrophic endometrium. We did not identify 
other studies in the literature that specifically evaluated polyps 
from tamoxifen users in relation to the atrophic endometrium 
to compare results. A previous study by Elkas et al (29) that 
evaluated benign endometrial samples from 20 tamoxifen 
users and 7 samples of atrophic endometrium from tamoxifen 
non-users, reported overexpression of ER and PR in the 
endometrial specimens of tamoxifen users compared to the 
controls. However, the patients included in the latter sample 
had received HT, which may have affected receptor expres-
sion (29).
A study by Schwartz et al (24) reported a higher PR 
expression in the glandular epithelium and a lower ER expres-
sion in the stroma of normal endometrium from women using 
tamoxifen when compared to atrophic controls. However, the 
authors of that study did not assess polyps (24).
A study by Dibi et al (15) that evaluated polyps and 
atrophic endometrium from tamoxifen users, reported a high 
progesterone expression in the polyps and the atrophic endo-
metrium and a higher ER expression in the polyps.
Despite the wide diversity among those studies, they all 
reported that the endometrium exhibited a higher PR expres-
sion under tamoxifen treatment, which was in agreement with 
the results of our study.
As regards polyps from tamoxifen users, our study demon-
strated a higher PR expression in the glandular epithelium 
and the stroma when compared to the polyps from non-users. 
Although there was a lower expression of ER in tamoxifen 
users, the difference was not statistically significant. The 
number of available similar studies in the literature is limited 
and the results are variable. Cohen et al (21) observed a lower 
ER expression in the epithelium and stroma of polyps from 
tamoxifen users, whereas McGurgan et al (22) reported this 
finding only in the epithelium and Schwartz et al (24) only 
in the stroma. As regards PR expression, McGurgan et al (22) 
demonstrated a higher expression in the stroma of polyps from 
tamoxifen users, whereas other studies did not report any 
difference (21,24).
Our study did not identify a higher ER expression in the 
polyps from tamoxifen non-users compared to those from 
tamoxifen users, as described by certain studies (17,21,24). 
This may be attributed to the fact that our tamoxifen non-user 
group had a higher body mass index (BMI). A previous study 
by Belisário et al (17) demonstrated that polyps removed from 
patients with a higher BMI exhibited a lower ER expression. 
Another factor that may have contributed to this result was the 
short period of tamoxifen use in our study, which had a mean 
duration of 31 months. In two previous studies conducted by 
Schwartz et al (24) and Cohen et al (21), the mean duration of 
tamoxifen use was 49 and 42 months, respectively.
Despite the heterogeneity of the studies and the results, 
assessing our results in conjunction with those reported in 
the literature, may lead to the conclusion that polyps exhibit a 
higher ER expression, regardless of tamoxifen use. These find-
ings are consistent with those of other studies demonstrating a 
higher ER expression in the polyps from tamoxifen non-users 
compared to that in the adjacent atrophic endometrium (15,23).
Tamoxifen appears to exert a limited effect on ER expres-
sion. Notably, this drug may act by increasing PR expression 
in endometrial polyps. This result is consistent with the histo-
logical findings in the polyps from tamoxifen users, which may 
present glandular secretory alterations and decidualization of 
the stroma, demonstrating a progestin effect (30,31).
ERs are nuclear receptors that bind to a ligand and act 
as potent transcription factors, controlling the expression of 
several genes, including those that encode PR (32,33). Thus, 
PR expression is not associated with the progestational status, 
but is a consequence of estrogen stimulation (34). Therefore, 
tamoxifen displays estrogen agonist activity, increasing the 
expression of PR in the endometrium.
The expression of ER seems to be linked to a process of 
self-regulation, dependent on hormonal factors, although this 
has not been fully elucidated (21). The increased expression of 
ER in polyps demonstrates a higher sensitivity of this type of 
tissue to estrogen.
A limitation of the present study is the immunohistochem-
ical scoring method used. Automation has emerged as a reliable 
approach to evaluate immunohistochemical results. However, in 
the present study, we decided to evaluate the immunostaining 
visually, since this was considered to be the optimal way to avoid 
misinterpretations due to the high heterogeneity of the quality 
of the stored specimens. As this was a retrospective study, 
the specimens were of heterogeneous morphologic quality, 
which may have interfered with staining (may have resulted in 
background staining). Despite the gain in standardization, auto-
mation bases its analysis in thresholds set by the investigator and 
scores every case thereafter. Thus, a spot in which background 
is present, may be erroneously scored. In this example, subjec-
tivity may be used in favor of reliability, as such a case may be 
eliminated from the analysis. In addition, previous studies have 
demonstrated the equivalence of the two methods (35,36).
In conclusion, our results suggest that polyps frequently 
exhibit increased ER levels that are not necessarily dependent 
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on the effect of tamoxifen. Furthermore, the high levels of PR 
appear to be consistent with the estrogenic effects of tamoxifen.
Although there appears to be a significant hormonal influ-
ence, the mechanism underlying the pathogenesis of a polyp 
has not been fully elucidated, neither has the precise effect of 
tamoxifen on the development of this endometrial alteration. 
It is hypothesized that additional mechanisms of action are 
involved.
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